Focused On-demand Library for Mitochondrial 2-oxoglutarate/malate carrier protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q02978

UPID:

M2OM_HUMAN

Alternative names:

Solute carrier family 25 member 11

Alternative UPACC:

Q02978; F5GY65; O75537; Q969P7

Background:

The Mitochondrial 2-oxoglutarate/malate carrier protein, also known as Solute carrier family 25 member 11, plays a crucial role in cellular metabolism. It facilitates the transport of 2-oxoglutarate across the inner mitochondrial membrane, exchanging it for malate and other dicarboxylic acids. This protein is integral to the malate-aspartate shuttle, gluconeogenesis from lactate, and nitrogen metabolism. It also maintains mitochondrial dynamics and protects against cytotoxic-induced apoptosis by modulating glutathione levels.

Therapeutic significance:

Given its involvement in Paragangliomas 6, a tumor predisposition syndrome, understanding the role of the Mitochondrial 2-oxoglutarate/malate carrier protein could unveil new therapeutic strategies. Its function in metabolic processes and mitochondrial integrity suggests potential targets for intervention in metabolic disorders and cancer.